PHI-1 dysregulation in cancer is driven by alterations at multiple levels—genetic, post-transcriptional, and post-translational—transforming it from a selective regulator to a broad-spectrum disruptor of PP1 signaling (Table 1). This evidence concerns the gene PPP1R14B and cancer.